Defining an Optimal Result of Transcatheter Tricuspid Valve Intervention: Results From the Tri-QOL Study

S Suzanne V. Arnold (Department of Medicine, University of Missouri–Kansas City School of Medicine, Kansas City) J John A. Spertus K Kensey Gosch (University of Missouri-Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute, Kansas City, MO (S.V.A., J.A.S., K.G., D.M.O., P.G.J.).) S Shannon M. Dunlay D Danielle M. Olds (University of Missouri-Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute, Kansas City, MO (S.V.A., J.A.S., K.G., D.M.O., P.G.J.).) P Philip G. Jones (University of Missouri-Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute, Kansas City, MO (S.V.A., J.A.S., K.G., D.M.O., P.G.J.).) S Saibal Kar (Los Robles Hospital and Medical Center, Thousand Oaks, CA) C Changfu Wu (US Food and Drug Administration, Silver Spring, MD (C.W.).) D David J. Cohen (Cardiovascular Research Foundation, New York)

Abstract

BACKGROUND: Recent randomized trials have demonstrated that for patients with severe tricuspid regurgitation (TR), transcatheter tricuspid valve interventions (TTVI) improve patients’ symptoms, function, and quality of life and that the amount of health status improvement correlates with the extent of TR reduction. Defining this relationship in greater detail can potentially provide insight into device selection and patient-specific treatment goals. We therefore sought to better understand the relationship between both baseline TR severity and change in TR after TTVI and the extent of improvement in health status after TTVI. METHODS: As part of the Tri-QOL (Kansas City Cardiomyopathy Questionnaire Validation in Tricuspid Valve Disease) study, data from 11 studies of TTVI devices were transferred to the US Food and Drug Administration to harmonize and anonymize before analysis by an independent center. This secondary, observational analysis used patient-level data from the 6 single-arm studies of patients who underwent TTVI to explore the association of change in KCCQ-OS with TR grade using multivariable models, adjusted for age, sex, chronic lung disease, and baseline KCCQ-OS. The primary model included TR grade at baseline, TR grade at 1 month, and the interaction between the two. RESULTS: Among 1056 patients with ≥severe TR who underwent TTVI, mean age was 79.1±7.1 years, 60.3% were female, and mean baseline Kansas City Cardiomyopathy Questionnaire-overall summary score [KCCQ-OS] was 49.5±22.3. Baseline TR grade was severe in 33.5%, massive in 35.9%, and torrential in 30.6%. One-month after TTVI, TR was none/trace in 21.7%, mild in 27.2%, moderate in 28.1%, and ≥evere in 23.1%, while the mean change in KCCQ-OS was 17.0±21.3 points. In a multivariable model that included TR grade at baseline, TR grade at 1 month, and their interaction, there was a strong association between reduction in TR and improvement in KCCQ-OS, with no consistent evidence of a threshold of TR grade below which there was no further improvement in KCCQ-OS. However, among patients with baseline torrential TR, the extent of health status improvement plateaued for patients achieving moderate or less TR at 1 month (ie, a 3-grade improvement from baseline). CONCLUSIONS: Health status improvement after TTVI was most strongly associated with the degree of TR reduction, although there was minimal additional improvement for most patients beyond a 3-grade reduction in TR. These findings support the goal of achieving mild or less TR with TTVI, although patients with torrential TR at baseline may be well served if moderate TR can be achieved.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue 5
Published February 03, 2026
Pages 310-318
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (9)

S

Suzanne V. Arnold

Department of Medicine, University of Missouri–Kansas City School of Medicine, Kansas City

J

John A. Spertus

K

Kensey Gosch

University of Missouri-Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute, Kansas City, MO (S.V.A., J.A.S., K.G., D.M.O., P.G.J.).

S

Shannon M. Dunlay

D

Danielle M. Olds

University of Missouri-Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute, Kansas City, MO (S.V.A., J.A.S., K.G., D.M.O., P.G.J.).

P

Philip G. Jones

University of Missouri-Kansas City’s Healthcare Institute for Innovations in Quality and Saint Luke’s Mid America Heart Institute, Kansas City, MO (S.V.A., J.A.S., K.G., D.M.O., P.G.J.).

S

Saibal Kar

Los Robles Hospital and Medical Center, Thousand Oaks, CA

C

Changfu Wu

US Food and Drug Administration, Silver Spring, MD (C.W.).

D

David J. Cohen

Cardiovascular Research Foundation, New York